Replies to post #117928 on Biotech Values

[iwfal]

I highly doubt that any all-oral HCV cocktails will be dosed in a sequential fashion.

I agree that you are correct in the near term (next several years) and probably right in the long term as well. In the near term it is virtually certain that they will want to explore other protocol factors that are considered more important (e.g. removal of ifn and/or rib). And in the long term it would have to show substantial benefit in the inevitable post-approval tweaking trials (e.g. change in breakthrough rate from 35% to 25%) before it would be explored enough to become SOC.